Literature DB >> 10231009

Immunity to heat shock proteins and arthritic disorders.

W van Eden1.   

Abstract

Adjuvant arthritis (AA) is a frequently used model of experimental arthritis. Because of its histopathology, which is reminiscent of rheumatoid arthritis in humans, AA is used as a model for the development of novel anti-inflammatory drugs. Recently, it has become evident that AA is a typical T-cell-mediated autoimmune condition. Therefore, novel immunotherapies targeted to T cells can be developed in this model. Analysis of responding T cells in AA have now led to the definition of various antigens with potential relevance to arthritis, including human arthritic conditions. One such antigen defined in AA is the 60kD heat shock protein. Both T-cell vaccination approaches and active antigen immunizations and antigen toleration approaches have turned out to be effective in suppressing AA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231009      PMCID: PMC1784715          DOI: 10.1155/S1064744999000101

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  22 in total

1.  Age differences in the intravenous glucose tolerance tests and the response to insulin.

Authors:  F A SILVERSTONE; M BRANDFONBRENER; N W SHOCK; M J YIENGST
Journal:  J Clin Invest       Date:  1957-03       Impact factor: 14.808

2.  Anergic T cells actively suppress T cell responses via the antigen-presenting cell.

Authors:  L S Taams; A J van Rensen; M C Poelen; C A van Els; A C Besseling; J P Wagenaar; W van Eden; M H Wauben
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

Review 3.  Do heat shock proteins control the balance of T-cell regulation in inflammatory diseases?

Authors:  W van Eden; R van der Zee; A G Paul; B J Prakken; U Wendling; S M Anderton; M H Wauben
Journal:  Immunol Today       Date:  1998-07

Review 4.  Mucosal modulation of immune responses to heat shock proteins in autoimmune arthritis.

Authors:  D Bonnin; S Albani
Journal:  Biotherapy       Date:  1998

Review 5.  Nasal administration of arthritis-related T cell epitopes of heat shock protein 60 as a promising way for immunotherapy in chronic arthritis.

Authors:  B Prakken; M Wauben; P van Kooten; S Anderton; R van der Zee; W Kuis; W van Eden
Journal:  Biotherapy       Date:  1998

6.  Stimulation of suppressive T cell responses by human but not bacterial 60-kD heat-shock protein in synovial fluid of patients with rheumatoid arthritis.

Authors:  J A van Roon; W van Eden; J L van Roy; F J Lafeber; J W Bijlsma
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

7.  Experimental immunization with anti-rheumatic bacterial extract OM-89 induces T cell responses to heat shock protein (hsp)60 and hsp70; modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis (RA).

Authors:  A Bloemendal; R Van der Zee; V P Rutten; P J van Kooten; J C Farine; W van Eden
Journal:  Clin Exp Immunol       Date:  1997-10       Impact factor: 4.330

8.  Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis.

Authors:  A B Prakken; W van Eden; G T Rijkers; W Kuis; E A Toebes; E R de Graeff-Meeder; R van der Zee; B J Zegers
Journal:  Arthritis Rheum       Date:  1996-11

9.  Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans.

Authors:  W van Eden; J Holoshitz; Z Nevo; A Frenkel; A Klajman; I R Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Lines of T lymphocytes induce or vaccinate against autoimmune arthritis.

Authors:  J Holoshitz; Y Naparstek; A Ben-Nun; I R Cohen
Journal:  Science       Date:  1983-01-07       Impact factor: 47.728

View more
  1 in total

1.  Mycobacterial heat shock protein 70 induces interleukin-10 production: immunomodulation of synovial cell cytokine profile and dendritic cell maturation.

Authors:  T Detanico; L Rodrigues; A C Sabritto; M Keisermann; M E Bauer; H Zwickey; C Bonorino
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.